← Back to Search

Rocatinlimab Dose 1 for Atopic Dermatitis (ROCKET-Outpost Trial)

Phase 3
Recruiting
Research Sponsored by Amgen
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to week 12
Awards & highlights

ROCKET-Outpost Trial Summary

The primary objective of this study is to assess successful self-administration of rocatinlimab subcutaneous using devices for injection at home.

Eligible Conditions
  • Atopic Dermatitis

ROCKET-Outpost Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to week 12 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of full-dose self-administered rocatinlimab injections as reported by participants or caregivers among attempted home-use injections at weeks 4 and 12 combined
Secondary outcome measures
Proportion of devices that have been reported with Product Complaints by participants, caregivers, or investigators among dispensed home-use devices at weeks 4 and 12 combined

ROCKET-Outpost Trial Design

2Treatment groups
Experimental Treatment
Group I: Rocatinlimab Dose 2Experimental Treatment1 Intervention
Rocatinlimab will be self-administered subcutaneously using a PFS. Participants will receive rocatinlimab Q4W for 52 weeks with a loading dose at week 2.
Group II: Rocatinlimab Dose 1Experimental Treatment1 Intervention
Rocatinlimab will be self-administered subcutaneously using a prefilled syringe (PFS). Participants will receive rocatinlimab every 4 weeks (Q4W) for 52 weeks with a loading dose at week 2.

Find a Location

Who is running the clinical trial?

AmgenLead Sponsor
1,371 Previous Clinical Trials
1,378,118 Total Patients Enrolled
MDStudy DirectorAmgen
915 Previous Clinical Trials
924,630 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe AD
2024. "A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe AD". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06224192.
All > Paid Studies Las Vegas > Meridian
~67 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top